Intermediate stage hepatocellular carcinoma
Authors:
- 1 July 2021
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 17 (3) , 740-748
Abstract
Context and Aims: The identification of inflammation-related prognostic heterogeneity in intermediate-stage hepatocellular carcinoma (HCC) can reveal more effective first-line treatments. Our study aimed to compare the intermediate-stage HCC patients' different inflammation-based scores in predicting their progression-free survival (PFS) after transarterial chemoembolization (TACE). Materials and Methods: We analyzed retrospectively a total of 128 intermediate-stage HCC patients who received first-line TACE treatment. We used the Cox-proportional hazards modeling to identify the independent prognostic factors. We compared the inflammation-based scores abilities to predict the PFS through the time-dependent receiver operating characteristic curves and area under the curves. Results: The multivariate analysis showed that tumor size and platelet-to-lymphocyte ratio (PLR) were the independent prognostic factors for PFS (P < 0.05). The PLR predicted the intermediate-stage HCC patients' PFS receiving the TACE treatment better than other inflammation-based scores (e.g., the neutrophil-to-lymphocyte ratio, the Glasgow Prognostic Score (GPS), the modified GPS, the Prognostic Index, the Prognostic Nutritional Index, the lymphocyte-to-monocyte ratio, and the systemic immune-inflammation index) (P < 0.05). An easy-to-use novel inflammation score based on tumor size – PLR-size score significantly improved the PFS prediction performance (P < 0.05). Conclusions: As a first-line treatment, TACE was not well suitable for all intermediate-stage HCC patients, while the PLR was a better inflammation-based score than others. Tumor size should be regarded as an essential variable in affecting intermediate-stage HCC patients' first-line treatment strategies.Keywords
This publication has 32 references indexed in Scilit:
- Peritransplant Lymphopenia Is a Novel Prognostic Factor in Recurrence of Hepatocellular Carcinoma After Liver TransplantationTransplantation, 2014
- A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)British Journal of Cancer, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Chronically inflamed livers up-regulate expression of inhibitory B7 family members #Hepatology, 2009
- Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadePLOS Pathogens, 2009
- Cancer-related inflammationNature, 2008
- Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinomaHepatology, 2007
- PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosisJournal of Hepatology, 2006